Protalix BioTherapeutics SG&A Expense (Quarterly) Analysis

Protalix BioTherapeutics Inc (PLX)

1.215 +0.02 (+1.25%) USD | NYAM | Apr 24, 16:00

1.215 0.00 (0.00%) After-Hours: 16:05

SG&A Expense (Quarterly) Chart

Historical SG&A Expense (Quarterly) Data

View and export this data back to 1999. Upgrade now.

Date	Value
December 31, 2023	4.143M
September 30, 2023	3.67M
June 30, 2023	4.031M
March 31, 2023	3.115M
December 31, 2022	3.098M
September 30, 2022	2.848M
June 30, 2022	2.611M
March 31, 2022	3.154M
December 31, 2021	3.466M
September 30, 2021	2.954M
June 30, 2021	3.171M
March 31, 2021	3.138M
December 31, 2020	2.951M
September 30, 2020	2.816M
June 30, 2020	2.194M
March 31, 2020	3.187M
December 31, 2019	3.014M
September 30, 2019	2.587M
June 30, 2019	2.068M
March 31, 2019	2.23M
December 31, 2018	2.172M
September 30, 2018	4.088M
June 30, 2018	2.158M
March 31, 2018	2.498M
December 31, 2017	3.343M

Date	Value
September 30, 2017	2.836M
June 30, 2017	2.814M
March 31, 2017	2.537M
December 31, 2016	3.141M
September 30, 2016	2.014M
June 30, 2016	2.206M
March 31, 2016	1.995M
December 31, 2015	1.293M
September 30, 2015	2.163M
June 30, 2015	2.001M
March 31, 2015	1.822M
December 31, 2014	1.939M
September 30, 2014	2.012M
June 30, 2014	1.566M
March 31, 2014	3.711M
December 31, 2013	1.986M
September 30, 2013	1.78M
June 30, 2013	2.182M
March 31, 2013	2.103M
December 31, 2012	2.41M
September 30, 2012	2.22M
June 30, 2012	3.504M
March 31, 2012	1.629M
December 31, 2011	1.617M
September 30, 2011	1.526M

SG&A Expense Definition

SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.

Read full definition.

SG&A Expense (Quarterly) Range, Past 5 Years

2.068M

Minimum

Jun 2019

4.143M

Maximum

Dec 2023

3.064M

Average

3.098M

Median

Dec 2022

SG&A Expense (Quarterly) Benchmarks